TechInvention Lifecare Pvt. Ltd. has formed a strategic alliance with Quantoom Biosciences, Belgium, to promote RNA-based vaccine development in India. The Memorandum of Understanding (MoU) was signed during the Belgian Economic Mission to India, in the presence of Her Royal Highness Princess Astrid of Belgium, industry leaders, and key stakeholders from both countries.
This partnership is intended to enhance India's biotech industry through the introduction of innovative RNA production solutions, with an emphasis on affordability, scalability, and accessibility.

Key Points of the Partnership
TechInvention and Quantoom Biosciences Collaborate for RNA-Based Vaccines

• TechInvention will bring Quantoom's innovative RNA production technologies to India.

• The project is centered on affordability, scalability, and accessibility of mRNA-based vaccines.

Setting Up End-to-End mRNA Production in India

• TechInvention's EU-GMP-certified Global Collaborative Centre for Medical Countermeasures (GCMC) at Mumbai will host RNA vaccine manufacturing.

• The centre will facilitate streamlined research, development, and commercialization of new RNA-based products.

A One Health Approach towards Human, Animal, and Environmental Health

• The low-carbon-footprint mRNA technology is supportive of global sustainability and climate-friendly healthcare initiatives.

• The partnership resonates with international efforts towards next-generation RNA vaccine accessibility for low- and middle-income countries (LMICs).

Industry Experts' Views
José Castillo, CEO, Quantoom Biosciences:
"Through Quantoom, our vision is to speed up the creation of mRNA vaccines. Our N-Force Toolbox will bring RNA products within reach and at scale anywhere in the world. Collaboration with TechInvention in India represents an important milestone toward this goal in the most populous nation in the world."

Syed Ahmed, Director & CEO, TechInvention:
"We are excited to introduce Quantoom's mRNA technology to India, revolutionizing RNA drug development and production. This alliance enhances India's readiness for future pandemics and makes RNA innovations in LMICs more accessible."

Impact on India's Biotech Industry

• Enhancing Pandemic Preparedness: Enhances India's capacity to quickly develop vaccines against future outbreaks.

• International RNA Innovation Hub: Locates India at the forefront of RNA-based medicines and vaccines.

• Technology Transfer: Boosts India's biotech strength with Belgium's state-of-the-art RNA production.

• Economic Growth: Provides a window of investment and employment for biopharmas in India.

This partnership solidifies India as a global hub for next-generation RNA vaccine production, keeping pace with the world's healthcare revolution. Through harnessing the power of cutting-edge RNA technology and domestic manufacturing capability, TechInvention and Quantoom look to speed up the availability and affordability of vaccines across the globe.
With this partnership, India moves closer to becoming a major hub for RNA-based medicines, furthering its role in global healthcare innovation.